ข่าวประชาสัมพันธ์ SWITCH 1 and 2

People With Diabetes May Achieve Improved Glycaemic Control With Tresiba(R) Versus Glargine U100, Without an Increase in Hypoglycaemia

According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with Tresiba(R) (insulin degludec) versus insulin glargine U100, without an increase in hypoglycaemia (potentially dangerous low blood sugar).[1] The results of this new analysis from the SWITCH 1 and 2 trials were presented today at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany

02 ตุลาคม 2561 16:59 น.

Tresiba(R) Reduces Hypoglycaemia Regardless of Blood Sugar Level

People with either type 1 or type 2 diabetes treated with Tresiba(R) had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.[1]... ธ.ค. 60

Tresiba(R) (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100

This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90... มิ.ย. 59